References

References

  1. Kendall-Taylor P 2003 Guidelines for the management of thyroid cancer. Clin Endocrinol 58:400–402.
  2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671.
  3. Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hufner M, Niederle B, Brabant G 2004 Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 112:52–58.
  4. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA Jr, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM 2007 Thyroid carcinoma. J Natl Compr Canc Netw 5:568–621.
  5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109–142.
  6. Jaquet AJ 1906 Ein fall von metastasierenden amyloidtumoren (lymphosarcoma). Virchows Archiv 185:251–267.
  7. Hazard JB, Hawk WA, Crile G Jr 1959 Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 19:152–161.
  8. Williams ED 1966 Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 19:114–118.
  9. Williams ED 1966 Diarrhoea and thyroid carcinoma. Proc R Soc Med 59:602–603.
  10. Williams ED, Brown CL, Doniach I 1966 Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid. J Clin Pathol 19:103–113.
  11. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 83:2638–2648.
  12. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D 2007 Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 33:493–497.
  13. Baloch ZW, LiVolsi VA 2001 Prognostic factors in welldifferentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 11:637–645.
  14. Paszko Z, Sromek M, Czetwertynska M, Skasko E, Czapczak D, Wisniewska A, Prokurat A, Chrupek M, Jagielska A, Kozlowicz-Gudzinska I 2007 The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindreds from Central Poland. Cancer Invest 25:742–749.
  15. Bergant D, Hocevar M, Besic N, Glavac D, Korosec B, Caserman S 2006 Hereditary medullary thyroid cancer in Slovenia—genotype-phenotype correlations. Wien Klin Wochenschr 118:411–416.
  16. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–460.
  17. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851–856.
  18. Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr, Goodfellow PJ 1994 Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 55:1076–1082.
  19. Schuffenecker I,Ginet N,GoldgarD, Eng C,Chambe B, Boneu A, Houdent C, Pallo D, Schlumberger M, Thivolet C, Lenoir GM 1997 Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d’Etude des Tumeurs a Calcitonine. Am J Hum Genet 60:233–237.
  20. Wolfe HJ, Melvin KE, Cervi-Skinner SJ, Saadi AA, Juliar JF, Jackson CE, Tashjian AH Jr 1973 C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 289: 437–441.
  21. LiVolsi VA 1997 C cell hyperplasia=neoplasia. J Clin Endocrinol Metab 82:39–41.
  22. Gimm O, Morrison CD, Suster S, Komminoth P, Mulligan L, Sweet KM 2004 Multiple endocrine neoplasia type 2. In: Dellellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon, pp 211–218.
  23. Sipple J 1961 The association of pheochromocytoma with carcinomas of the thyroid gland. Am J Med 31:163–166.
  24. Steiner AL, Goodman AD, Powers SR 1968 Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2. Medicine 47:371–409.
  25. Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B, Januszewicz A, Eng C 2007 Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 357:1311–1315.
  26. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA Jr 1986 Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73:278–281.
  27. Wagenmann A 1922 Multiple neurome des Auges und der Zunge. Ber Dtsch Ophthal 43:282–285.
  28. Froboese C 1923 Das aus markhaltigen nervenfascern bestehende gangliezellenlose echte neurom in rankenformzugleich ein beitrag zu den nervosen Geschwulsten der zunge und des augenlides. Virchows Arch Pathol Anat 240:312–327.
  29. Williams ED, Pollock DJ 1966 Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen’s disease. J Pathol Bacteriol 91:71–80.
  30. Takahashi M, Ritz J, Cooper GM 1985 Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581–588.
  31. Mathew CG, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, Fong SL, Bridges CD, Haak H, Kruseman AC, Schifter S, Hansen HH, Telenius H, Telenius-Berg M, Ponder BAJ 1987 A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527–528.
  32. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, Ponder BAJ 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237–241.
  33. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91:1579–1583.
  34. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, Lips CJ, Buys CH 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375–376.
  35. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM 2006 RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27:535– 560.
  36. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F 1996 Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619–1622.
  37. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687.
  38. Miccoli P, Minuto MN, Ugolini C, Molinaro E, Basolo F, Berti P, Pinchera A, Elisei R 2007 Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer 14:1099–1105.
  39. Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q, Eisenberger CF, Roher HD, Knoefel WT 2007 Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821.
  40. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’e´tude des tumeurs a` calcitonine. Clin Endocrinol 48:265–273.
  41. Greene FL, Page DL, Fleming ID, Fritz A, Balch DM 2003 AJCC Cancer Staging Manual, 6th edition. Springer Verlag, Chicago.
  42. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J 2005 Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 200:890–896.
  43. Roman S, Lin R, Sosa JA 2006 Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142.
  44. Hansford JR, Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37:817–827.
  45. Iihara M, Yamashita T, Okamoto T, Kanbe M, Yamazaki K, Egawa S, Yamaguchi K, Obara T 1997 A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. Jpn J Clin Oncol 27:128–134.
  46. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thiobodeau SN, Lacroix A, Frilling A, Ponder, BAJ, Mulligan LM 1996 The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579.
  47. Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D, Gangi E, Beck-Peccoz P 2003 Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol 59:156–161.
  48. Brauckhoff M, Gimm O, Hinze R, Ukkat J, Brauckhoff K, Dralle H 2002 Papillary thyroid carcinoma in patients with RET proto-oncogene germlinemutation. Thyroid 12:557–561.
  49. Eng C 1996 Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung’s disease. N Engl J Med 335:943–951.
  50. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martucciello G 1998 Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 243:515–520.
  51. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ 1994 Diverse phenotypes associated with exon 10 mutations of the RET protooncogene. Hum Mol Genet 3:2163–2167.
  52. Moers AM, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IA, Blijham GH, Hoppener JW, Vroom TM, van Amstel HK, Lips CJ 1996 Familial medullary thy-roid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101:635–641.
  53. Machens A, Dralle H 2006 Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol 247:34–40.
  54. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104– 1109.
  55. O’Riordain DS, O’Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, van Heerden JA 1994 Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116:1017–1023.
  56. Jackson CE, Talpos GB, Block MA, Norum RA, Lloyd RV, Tashjian AH Jr 1984 Clinical value of tumor doubling estimations in multiple endocrine neoplasia type II. Surgery 96:981–987.
  57. Brunt LM, Wells SA Jr 1987 Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am 67:263–279.
  58. O’Riordain DS, O’Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA 1995 Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 118:936– 942.
  59. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr 1996 Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 31:177–181; discussion 181–172.
  60. Kaufman FR, Roe TF, Isaacs H Jr, Weitzman JJ 1982 Metastatic medullary thyroid carcinoma in young children with mucosal neuroma syndrome. Pediatrics 70:263–267.
  61. Wygoda Z, Oczko-Wojciechowska M, Gubała E, Pawlaczek A, Kula D, Wiench M, Włoch J 2006 [Medullary thyroid carcinoma: the comparison of the hereditary and sporadic types of cancer]. Endokrynol Pol 57:407–414. (In Polish.)
  62. de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP 2006 Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65:729–736.
  63. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H 2005 Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999–4003.
  64. Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M, Baudin E 2002 Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer 94:44–50.
  65. Samaan NA, Draznin MB, Halpin RE, Bloss RS, Hawkins E, Lewis RA 1991 Multiple endocrine syndrome type IIb in early childhood. Cancer 68:1832–1834.
  66. Smith VV, Eng C, Milla PJ 1999 Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 2B: implications for treatment. Gut 45:143–146.
  67. Unruh A, Fitze G, Janig U, Bielack S, Lochbuhler H, Coerdt W 2007 Medullary thyroid carcinoma in a 2-month-old male with multiple endocrine neoplasia 2B and symptoms of pseudo-Hirschsprung disease: a case report. J Pediatr Surg 42:1623–1626.
  68. Yin M, King SK, Hutson JM, Chow CW2006 Multiple endocrine neoplasia type 2B diagnosed on suction rectal biopsy in infancy: a report of 2 cases. Pediatr Dev Pathol 9:56–60.
  69. Carney JA, Go VL, Sizemore GW, Hayles AB 1976 Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b. N Engl J Med 295:1287–1291.
  70. Brauckhoff M, Machens A, Hess S, Lorenz K, Gimm O, Brauckhoff K, Sekulla C, Dralle H 2008 Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144:1044–1051.
  71. Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellini P, Leyland J, Pierotti MA, Whittaker J, Taylor SS, Bongarzone I, Ponder BA 2006 RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 66:10179–10187.
  72. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K 1999 Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90:1–5.
  73. Kameyama K, Okinaga H, Takami H 2004 RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed Pharmacother 58:345–347.
  74. Iwashita T, Murakami H, Kurokawa K, Kawai K, Miyauchi A, Futami H, Qiao S, Ichihara M, Takahashi M 2000 A twohit model for development of multiple endocrine neoplasia type 2B by RET mutations. Biochem Biophys Res Commun 268:804–808.
  75. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA 1995 Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123–127.
  76. Bugalho MJ, Domingues R, Santos JR, Catarino AL, Sobrinho L 2007 Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141:90–95.
  77. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF 1996 Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740–3745.
  78. Telander RL, Zimmerman D, Sizemore GW, van Heerden JA, Grant CS 1989 Medullary carcinoma in children. Results of early detection and surgery. Arch Surg 124:841–843.
  79. Wells SA Jr, Baylin SB, Gann DS, Farrell RE, Dilley WG, Preissig SH, Linehan WM, Cooper CW 1978 Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Ann Surg 188:377–383.
  80. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W, Raue F 2006 Longterm outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155:229–236.
  81. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New Engl J Med 353:1105–1113.
  82. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H 2005 Advances in the management of hereditary medullary thyroid cancer. J Intern Med 257:50–59.
  83. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB 2003 Multiple endocrine neoplasia type 2: evaluation of the genotypephenotype relationship. Arch Surg 138:409–416; discussion 416.
  84. Szinnai G, Meier C, Komminoth P, Zumsteg UW 2003 Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 111:E132–139.
  85. Quayle FJ, Fialkowski EA, Benveniste R, Moley JF 2007 Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142:800–805; discussion 805.e1.
  86. Frank-Raue K, Machens A, Scheuba C, Niederle B, Dralle H, Raue F 2008 Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clin Endocrinol 69:259–263.
  87. Lips CJ 1998 Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med 243:589–594.
  88. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton- Bligh P, Robinson BG 1996 The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 44:213–220.
  89. Shaha AR, Cohen T, Ghossein R, Tuttle RM 2006 Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members. Laryngoscope 116:1704–1707.
  90. Dabir T, Hunter SJ, Russell CF, McCall D, Morrison PJ 2006 The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma—only phenotype with incomplete penetrance: implications for screening and management of carrier status. Fam Cancer 5:201–204.
  91. Frohnauer MK, Decker RA 2000 Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 128:1052–1057;discussion 1057–1058.
  92. Wells SA Jr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW 1978 Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 188:139–141.
  93. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M 1996 Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 129:459–464.
  94. Machens A, Schneyer U, Holzhausen HJ, Dralle H 2005 Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029–2034.
  95. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA 2008 Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 93:3058–3065.
  96. van Heurn LW, Schaap C, Sie G, Haagen AA, Gerver WJ, Freling G, van Amstel HK, Heineman E 1999 Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 34:568–571.
  97. Mulligan LM 2004 From genes to decisions: evolving views of genotype-based management in MEN 2. Cancer Treat Res 122:417–428.
  98. GeneTests: Medical Genetics Information Resource (database online). Available at http:www.genetests.org. Accessed August 29, 2008.
  99. Kaldrymides P, Mytakidis N, Anagnostopoulos T, Vassiliou M, Tertipi A, Zahariou M, Rampias T, Koutsodontis G, Konstantopoulou I, Ladopoulou A, Bei T, Yannoukakos D 2006 A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clin Endocrinol 64:561–566.
  100. Dvorakova S, Vaclavikova E, Duskova J, Vlcek P, Ryska A, Bendlova B 2005 Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest 28:905–909.
  101. Menko FH, van der Luijt RB, deValk IA, TooriansAW, Sepers JM, van Diest PJ, Lips CJ 2002 Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin EndocrinolMetab 87:393–397.
  102. Tarasoff v Regents of University of Calif, 551 P2d 334 (1976).

102a. Rosenthal MS, Pierce HH 2005 Inherited medullary thyroid cancer and the duty to warn: Revisiting Pate v. Threlkel in light of HIPAA. Thyroid 15:140–145

  1. Malloy v Meier, 629 NW2d 711 (Minn 2004).
  2. Pate v Threlkel, 661 So 2d 278 (Fla 1995).
  3. Safer v Estate of T. Pack, 677 A 2d 1188 (NJ Supp 1996).
  4. American Society of Clinical Oncology 2003 American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397–2406.
  5. American Medical Association. Opinion 2.131 Disclosure of familial risk in genetic testing. Code of Medical Ethics. http://www.ama-assn.org/ama/pub/physician-resources/ medical-ethics/code-medical-ethics/opinion2131.shtml accessed May 13, 2009.
  6. Godard B, Hurlimann T, Letendre M, Egalite N 2006 Guidelines for disclosing genetic information to family members: from development to use. Fam Cancer 5:103–116.
  7. Fleisher LD, Cole LJ 2001 Health Insurance Portability and Accountability Act is here: what price privacy? Genet Med 3:286–289.
  8. Gostin LO 2001 National health information privacy: regulations under the Health Insurance Portability and Accountability Act. JAMA 285:3015–3021.
  9. 1996 Health Insurance Portability and Accountability Act. Vol Public Law No 104–191.
  10. Huang SM, Tao BL, Tzeng CC, Liu HT, Wang WP 1997 Prenatal molecular diagnosis of RET proto-oncogene mutation in multiple endocrine neoplasia type 2A. J Formos Med Assoc 96:542–544.
  11. Martinelli P, Maruotti GM, Pasquali D, Paladini D, Agangi A, Rippa E, Colantuoni V, Bellastella A, Sinisi AA 2004 Genetic prenatal RET testing and pregnancy management of multiple endocrine neoplasia Type II A (MEN2A): a case report. J Endocrinol Invest 27:357–360.
  12. Offit K, Kohut K, Clagett B, Wadsworth EA, Lafaro KJ, Cummings S, White M, Sagi M, Bernstein D, Davis JG 2006 Cancer genetic testing and assisted reproduction. J Clin Oncol 24:4775–4782.
  13. Offit K, Sagi M, Hurley K 2006 Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. JAMA 296:2727–2730.
  14. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K 2002 Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26:1023–1028.
  15. Moley JF, DeBenedetti MK 1999 Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880–887; discussion 887–888.
  16. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH 2000 Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–1148.
  17. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E 2001 Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130:1044–1049.
  18. Scopsi L, Sampietro G, Boracchi P, Del Bo R, Gullo M, Placucci M, Pilotti S 1996 Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78:2173–2183.
  19. Beressi N, Campos JM, Beressi JP, Franc B, Niccoli-Sire P, Conte-Devolx B, Murat A, Caron P, Baldet L, Kraimps JL, Cohen R, Bigorgne JC, Chabre O, Lecomte P, Modigliani E 1998 Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid 8: 1039–1044.
  20. Decker RA, Peacock ML, Borst MJ, Sweet JD, Thompson NW 1995 Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 118:257–263; discussion 263–254.
  21. Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA Jr 1997 Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 14: 3103–3106.
  22. Wiench M, Wygoda Z, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Krawczyk Z, Jarzab B 2001 Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 19:1374–1380.
  23. Jones BA, Sisson JC 1983 Early diagnosis and thyroidectomy in multiple endocrine neoplasia, type 2b. J Pediatr 102:219–223.
  24. Erdogan MF, Gursoy A, Gullu S, Aydintug S, Kucuk B, Baskal N, Kamel N, Hoppner W, Erdogan G 2007 Clinical and genetic experience in Turkish multiple endocrine neoplasia type 2 families. Endocrinologist 17:273–277.
  25. Barontini M, Levin G, Sanso G 2006 Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci 1073:30–37.
  26. De Krijger RR, Petri BJ, Van Nederveen FH, Korpershoek E, De Herder WW, De Muinck Keizer-Schrama SM, Dinjens WN 2006 Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci 1073:166–176.
  27. Mora J, Cascon A, Robledo M, Catala A 2006 Pediatric paraganglioma: an early manifestation of an adult disease secondary to germline mutations. Pediatr Blood Cancer 47:785–789.
  28. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez- Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS 2007 Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 3:92–102.
  29. Jackson MB, Guttenberg M, Hedrick H, Moshang T Jr 2005 Multiple endocrine neoplasia type 2A in a kindred with C634Y mutation. Pediatrics 116:e468–471.
  30. Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M, Peacock ML 1996 Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 20:814–820; discussion 820–811.
  31. Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F, Sarfati E, Dupond JL, Maes B, Travagli JP, Boneu A, Roger P, Houdent C, Barbier J, Modigliani E 1996 Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d’Etude des Tumeurs a` Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 20:808–812; discussion 812–803.
  32. Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B 1995 Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238:369–373.
  33. Bevilacqua M, Dominguez LJ, Righini V, Valdes V, Vago T, Leopaldi E, Baldi G, Barrella M, Barbagallo M 2006 Dissimilar PTH, gastrin, and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia, primary hyperparathyroidism, and normal subjects: a useful tool for differential diagnosis. J Bone Miner Res 21: 406–412.
  34. Krebs NF, Reidinger CJ, Robertson AD, Brenner M 1997 Bone mineral density changes during lactation: maternal, dietary, and biochemical correlates.AmJ Clin Nutr 65:1738– 1746.
  35. Ritchie LD, Fung EB, Halloran BP, Turnlund JR, Van Loan MD, Cann CE, King JC 1998 A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 67: 693–701.
  36. Prentice A, Jarjou LM, Stirling DM, Buffenstein R, Fairweather-Tait S 1998 Biochemical markers of calcium and bone metabolism during 18 months of lactation in Gambian women accustomed to a low calcium intake and in those consuming a calcium supplement. J Clin Endocrinol Metab 83:1059–1066.
  37. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr 2004 Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512–1525.
  38. Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, Goldberg RL, Becker KL 1998 Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 83:3296–3301.
  39. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C 1994 Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605– 1608.
  40. d’Herbomez M, Caron P, Bauters C, Cao CD, Schlienger JL, Sapin R, Baldet L, Carnaille B, Wemeau JL 2007 Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 157:749–755.
  41. Verga U, Morpurgo PS, Vaghi I, Radetti G, Beck-Peccoz P 2006 Normal range of calcitonin in children measured by a chemiluminescent two-site immunometric assay. Horm Res 66:17–20.
  42. Basuyau JP, Mallet E, Leroy M, Brunelle P 2004 Reference intervals for serum calcitonin in men, women, and children. Clin Chem 50:1828–1830.
  43. Niccoli P, Conte-Devolx B, Lejeune PJ, Carayon P, Henry JF, Roux F, Wion-Barbot N, Bigorgne JC 1996 [Hypercalcitoninemia in conditions other than medullary cancers of the thyroid]. Ann Endocrinol (Paris) 57:15–21. (In French.)
  44. Karanikas G, Moameni A, Poetzi C, Zettinig G, Kaserer K, Bieglmayer C, Niederle B, Dudczak R, Pirich C 2004 Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab 89:515–519.
  45. Schuetz M, Duan H, Wahl K, Pirich C, Antoni A, Kommata S, Kletter K, Dudczak R, Karanikas G, Willheim M 2006 T lymphocyte cytokine production patterns in Hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Anticancer Res 26:4591–4596.
  46. Borchhardt KA, Heinzl H, Gessl A, Horl WH, Kaserer K, Sunder-Plassmann G 2006 Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or c-cell hyperplasia. Kidney Int 70:2014–2020.
  47. Borchhardt KA, Horl WH, Sunder-Plassmann G 2005 Reversibility of ‘secondary hypercalcitoninemia’ after kidney transplantation. Am J Transplant 5:1757–1763.
  48. Butterfield JH, Tefferi A, Kozuh GF 2005 Successful treatment of systemic mastocytosis with high-dose interferonalfa: long-term follow-up of a case. Leuk Res 29:131–134.
  49. Butterfield JH, Li CY 2004 Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am J Clin Pathol 121:264–267.
  50. Yocum MW, Butterfield JH, Gharib H 1994 Increased plasma calcitonin levels in systemic mast cell disease. Mayo Clin Proc 69:987–990.
  51. Lundin A, Oberg K 1984 Hypercalcitoninaemia in a patient with urticaria pigmentosa. A possible cause of diarrhoea. Acta Med Scand 215:281–285.
  52. Vitale G, Ciccarelli A, Caraglia M, Galderisi M, Rossi R, Del Prete S, Abbruzzese A, Lupoli G 2002 Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin Chem 48:1505–1510.
  53. Leboeuf R, Langlois MF, Martin M, Ahnadi CE, Fink GD 2006 ‘‘Hook effect’’ in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. J Clin Endocrinol Metab 91:361–364.
  54. Preissner CM, Dodge LA, O’Kane DJ, Singh RJ, Grebe SK 2005 Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem 51:208–210.
  55. Tommasi M, Brocchi A, Cappellini A, Raspanti S, Mannelli M 2001 False serum calcitonin high levels using a noncompetitive two-site IRMA. J Endocrinol Invest 24:356– 360.
  56. Papapetrou PD, Polymeris A, Karga H, Vaiopoulos G 2006 Heterophilic antibodies causing falsely high serum calcitonin values. J Endocrinol Invest 29:919–923.
  57. Machens A, Haedecke J, Holzhausen HJ, Thomusch O, Schneyer U, Dralle H 2000 Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbecks Arch Surgery 385:398–401.
  58. Kaye TB 1995 PTHrP-mediated hypercalcemia in a calcitoninproducing islet cell tumor. Endocr Pract 1:170–171.
  59. Machens A, Haedecke J, Hinze R, Thomusch O, Schneyer U, Dralle H 2000 Hypercalcitoninemia in a sporadic asymptomatic neuroendocrine tumor of the pancreatic tail. Dig Surg 17:522–524.
  60. Pusztai P, Sarman B, Illyes G, Szekely E, Peter I, Boer K, Tihanyi T, Racz K 2006 Hypercalcitoninemia in a patient with a recurrent goitre and insulinoma: a case report. Exp Clin Endocrinol Diabetes 114:217–221.
  61. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV 1996 The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 75:53–63.
  62. Jackson C, Buchman AL 2005 Calcitonin-secreting VIPoma. Dig Dis Sci 50:2203–2206.
  63. Eskens FA, Roelofs EJ, Hermus AR, Verhagen CA 1997 Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitonin. Anticancer Res 17: 4667–4670.
  64. Calhoun K, Toth-Fejel S, Cheek J, Pommier R 2003 Serum peptide profiles in patients with carcinoid tumors. Am J Surg 186:28–31.
  65. Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ 1996 Serum calcitonin in small cell carcinoma of the prostate. Ann Clin Lab Sci 26:487–495.
  66. Pratz KW, Ma C, Aubry MC, Vrtiska TJ, Erlichman C 2005 Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. Mayo Clin Proc 80:116–120.
  67. Suzuki H 1998 Calcitonin levels in normal individuals with new highly sensitive chemiluminescent enzyme immunoassay. J Clin Lab Anal 12:218–222.
  68. Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O, Saint-Andre JP 1997 Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 82:42–47.
  69. Pedrazzoni M, Ciotti G, Davoli L, Pioli G, Girasole G, Palummeri E, Passeri M 1989 Meal-stimulated gastrin release and calcitonin secretion. J Endocrinol Invest 12:409–412.
  70. Brandsborg M, Nielsen HE, Brandsborg O, Olsen KJ, Lovgreen NA 1980 The role of serum gastrin in the secretion of calcitonin: studies in patients with pernicious anaemia and in healthy subjects. Scand J Gastroenterol 15:23–28.
  71. Howe JC 1990 Postprandial response of calcium metabolism in postmenopausal women to meals varying in protein level=source. Metab Clin Exp 39:1246–1252.
  72. Filipponi P, Gregorio F, Cristallini S, Mannarelli C, Blass A, Scarponi AM, Vespasiani G 1990 Partial gastrectomy and mineral metabolism: effects on gastrin-calcitonin release. Bone Miner 11:199–208.
  73. Talmage RV, Grubb SA, Norimatsu H, Vanderwiel CJ 1980 Evidence for an important physiological role for calcitonin. Proc Natl Acad Sci U S A 77:609–613.
  74. Lee NC, Norton JA 2000 Multiple endocrine neoplasia type 2B—genetic basis and clinical expression. Surg Oncol 9:111– 118.
  75. Niccoli-Sire P, Murat A, Rohmer V, Gibelin H, Chabrier G, Conte-Devolx B, Visset J, Ronceray J, Jaeck D, Henry JF, Proye C, Carnaille B, Kraimps JL 2003 When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? Surgery 134:1029–1036; discussion 1036–1027.
  76. Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R, Niederle B 2007 Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience. Surgery 142:1003–1010; discussion 1010 e1001–1003.
  77. Yoshimoto K, Iwahana H, Itakura M 1993 Relatively good prognosis of multiple endocrine neoplasia type 2B in Japanese: review of cases in Japan and analysis of genetic changes in tumors. Endocr J 40:649–657.
  78. Wray CJ, Rich TA, Waguespack SG, Lee JE, Perrier ND, Evans DB 2008 Failure to recognize multiple endocrine neoplasia 2B: more common than we think? Ann Surg Oncol 15:293–301.
  79. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr 1996 Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Ann Surg 223:472– 478; discussion 478–480.
  80. O’Riordain DS, O’Brien T, Grant CS, Weaver A, Gharib H, van Heerden JA 1993 Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 114:1031–1037; discussion 1037–1039.
  81. van Heerden JA, Kent RB, 3rd, Sizemore GW, Grant CS, ReMine WH 1983 Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes. Surgical experience. Arch Surg 118:533–536.
  82. Herfarth KK, Bartsch D, Doherty GM, Wells SA Jr, Lairmore TC 1996 Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120:966–973; discussion 973–964.
  83. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D 2005 Cinacalcet hydrochloride maintains longterm normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135–141.
  84. Chang TC, Wu SL, Hsiao YL 2005 Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET protooncogene mutations. Acta Cytolog 49:477–482.
  85. Papaparaskeva K, Nagel H, Droese M 2000 Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol 22:351–358.
  86. Bugalho MJ, Santos JR, Sobrinho L 2005 Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 91:56–60.
  87. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F 2004 Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168.
  88. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S 2007 Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450–455.
  89. Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezzi C, Fadda G, Baldini A, Carani C, Pontecorvi A, Roti E 2006 Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. J Endocrinol Invest 29:427–437.
  90. Henry JF, Denizot A, Puccini M, Gramatica L, Kvachenyuk A, Conte Devolx B, De Micco C 1998 Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J Surg 22:752–756; discussion 756–757.
  91. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH, Chung JH 2001 Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 11:73–80.
  92. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E, Conte-Devolx B 1997 Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 82:338–341.
  93. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A 1994 Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 78: 826–829.
  94. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL, Fombeur JP 1995 Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 42:453–460.
  95. Vantyghem MC, Pigny P, Leteurtre E, Leclerc L, Bauters C, Douillard C, D’Herbomez M, Carnaille B, Proye C, Wemeau JL, Lecomte-Houcke M 2004 Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation. Thyroid 14:842–847.
  96. Vierhapper H, Niederle B, Bieglmayer C, Kaserer K, Baumgartner-Parzer S 2005 Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 15:1267–1272.
  97. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B 1997 Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 82:1589–1593.
  98. Borget I, De Pouvourville G, Schlumberger M 2007 Editorial. Calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab 92:425–427.
  99. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA 2008 Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 93:2173–2180.
  100. Kudo T, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M 2007 Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 17:635–638.
  101. Boi F, Maurelli I, Pinna G, Atzeni F, Piga M, Lai ML, Mariotti S 2007 Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:2115–2118.
  102. Redding AH, Levine SN, Fowler MR 2000 Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 10:919–922.
  103. Asari R, Scheuba C, Kaczirek K, Niederle B 2006 Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg 141:1199–1205; discussion 1205.
  104. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M 2007 Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92:4185– 4190.
  105. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F 2005 High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90:779– 788.
  106. Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ 2008 Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid 18:901– 905.
  107. Lecle`re J, Sidibe´ S, Lassau N, Gardet P, Caillou B, Schlumberger M, Romaniuk C, Parmentier C 1996 [Ultrasonographic aspects of hepatic metastases of thyroid medullary cancers]. Journal de radiologie 77:99–103. (In French.)
  108. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, EvansDB 2003Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134:890–899; discussion 899–901.
  109. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallie E, Barbet J, Goldenberg DM, Chatal JF, Kraeber- Bodere F 2007 Sensitivity and prognostic value of positron emission tomography with f-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 92:4590–4597.
  110. Giraudet AL, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M 2008 Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246.
  111. Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A, Krivitzky A, Modigliani E 2001 Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol 55:403–409.
  112. Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C 2008 Longterm prognosis of medullary thyroid carcinoma. Clin Endocrinol 69:497–505.
  113. Leggett MD, Chen SL, Schneider PD, Martinez SR 2008 Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma. Ann Surg Oncol 15:2493–2499.
  114. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070–2075.
  115. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H 2000 Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909–1915.
  116. Machens A, Hauptmann S, Dralle H 2008 Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586–591.
  117. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R 1994 Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24:112–121.
  118. Fialkowski EA, Moley JF 2006 Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 94:737–747.
  119. Frilling A, Weber F, Tecklenborg C, Broelsch CE 2003 Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET protooncogene. Langenbecks Arch Surg 388:17–26.
  120. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, HoppnerW1998 Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744–750; discussion 750–741.
  121. Machens A, Hinze R, Thomusch O, Dralle H 2002 Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28.
  122. Quayle FJ, Benveniste R, DeBenedetti MK, Wells SA, Moley JF 2004 Hereditary medullary thyroid carcinoma in patients greater than 50 years old. Surgery 136:1116– 1121.
  123. Eng C 1999 RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380–393.
  124. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG 1996 Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44: 249–257.
  125. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G 1995 Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80:3088–3090.
  126. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90: 6077–6084.
  127. Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC 1979 Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 43:825–837.
  128. Fugazzola L, Pinchera A, Luchetti F, Iacconi P, Miccoli P, Romei C, Puccini M, Pacini F 1994 Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 9:21–24.
  129. Engelbach M, Gorges R, Forst T, Pfutzner A, Dawood R, Heerdt S, Kunt T, Bockisch A, Beyer J 2000 Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 85:1890–1894.
  130. Tisell LE, Dilley WG, Wells SA Jr 1996 Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 119:34– 39.
  131. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP 2008 18FDihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation. J Nucl Med 49:524–531.
  132. Diez JJ, Iglesias P 2004 Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 14:984–985.
  133. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB 2003 Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134:946–954; discussion 954–945.
  134. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P, Tron L 2002 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66–71.
  135. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F 2001 Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676.
  136. Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C,MerinoMJ, Pacak K 2003 Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 88:637–641.
  137. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E 2001 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64–71.
  138. Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, Al-Nahhas A, Gross MD 2008 The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 34:581–586.
  139. Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M, Shaha AR, Tuttle RM, Shah JP, Larson SM 2007 Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 48:501–507.
  140. Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM 2005 A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620–633.
  141. Czepczyn´ ski R, Kosowicz J, Ziemnicka K, Mikołajczak R, Gryczyn´ ska M, Sowin´ ski J 2006 [The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma]. Endokrynol Pol 57:431–435. (In Polish.)
  142. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C 1996 Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 37:912–916.
  143. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, Krenning EP 1993 In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413–1417.
  144. Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F 1995 Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 42:31– 37.
  145. Eising EG, Farahati J, Bier D, Knust EJ, Reiners C 1995 [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors]. Nuklearmedizin 34:1–7. (In German.)
  146. Finny P, Jacob JJ, Thomas N, Philip J, Rajarathnam S, Oommen R, Nair A, Seshadri MS 2007 Medullary thyroid carcinoma: a 20-year experience from a centre in South India. ANZ J Surg 77:130–134.
  147. Behr TM, Gratz S, Markus PM, Dunn RM, Hufner M, Schauer A, Fischer M, Munz DL, Becker H, Becker W 1997 Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 80:2436–2457.
  148. Gao ZR, An R, Zhang YX, Biersack HJ 2006 [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma]. Zhonghua Zhong Liu Za Zhi [Chinese journal of oncology] 28:621–624. (In Chinese.)
  149. Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR, Muller-Brand J, Walter MA 2007 Response to [90Yttrium-DOTA]-TOC treatment is associated with longterm survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13:6696– 6702.
  150. Tamagnini P, Bernante P, Piotto A, Toniato A, Pelizzo MR 2001 [Reoperation of medullary thyroid carcinoma: longterm results]. Ann Chir (In French.) 126:762–767.
  151. Kebebew E, Kikuchi S, Duh QY, Clark OH 2000 Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135:895–901.
  152. Tisell LE, Jansson S 1988 Recent results of reoperative surgery in medullary carcinoma of the thyroid. Wien Klin Wochenschr 100:347–348.
  153. Tisell LE, Hansson G, Jansson S, Salander H 1986 Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60–66.
  154. Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells SA 1998 Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med 243:521– 526.
  155. Dralle H 2002 Lymph node dissection and medullary thyroid carcinoma. Br J Surg 89:1073–1075.
  156. Fialkowski E, Debenedetti M, Moley J 2008 Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32:754–765.
  157. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM 1990 Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395–400; discussion 400–401.
  158. Moley JF, Fialkowski EA 2007 Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946–956.
  159. Isozaki T, Kiba T, Numata K, Saito S, Shimamura T, Kitamura T, Morita K, Tanaka K, Sekihara H 1999 Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. Intern Med 38:17–21.
  160. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A 1996 Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77:402–408.
  161. Deftos LJ, Stein MF 1980 Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 50:967–968.
  162. Hellman DE, Kartchner M, Van Antwerp JD, Salmon SE, Patton DD, O’Mara R 1979 Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 48:451–455.
  163. Tung WS, Vesely TM, Moley JF 1995 Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 118:1024–1029; discussion 1029–1030.
  164. Moley JF, Dilley WG, DeBenedetti MK 1997 Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 225:734–740; discussion 740–743.
  165. Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL 2005 Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 115:1445– 1450.
  166. Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y 1984 Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199: 461–466.
  167. Saad MF, Fritsche HA Jr, Samaan NA 1984 Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58:889–894.
  168. Gautvik KM, Talle K, Hager B, Jorgensen OG, Aas M 1989 Early liver metastases in patients with medullary carcinoma of the thyroid gland. Cancer 63:175–180.
  169. Szavcsur P, Godeny M, Bajzik G, Lengyel E, Repa I, Tron L, Boer A, Vincze B, Poti Z, Szabolcs I, Esik O 2005 Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol 31:183–190.
  170. Schott M, Willenberg HS, Sagert C, Nguyen TB, Schinner S, Cohnen M, Cupisti K, Eisenberger CF, Knoefel WT, Scherbaum WA 2007 Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery. Clin Endocrinol 66:405–409.
  171. Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M 2003 Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:1537–1542.
  172. Abdelmoumene N, Schlumberger M, Gardet P, Roche A, Travagli JP, Francese C, Parmentier C 1994 Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer 69:1141–1144.
  173. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI 2008 Postoperative radiotherapy for advanced medullary thyroid cancer—local disease control in the modern era. Head Neck 30:883–888.
  174. Chow SM, Chan JK, Tiu SC, Choi KL, Tang DL, Law SC 2005 Medullary thyroid carcinoma in Hong Kong Chinese patients. Hong Kong Med J 11:251–258.
  175. Fife KM, Bower M, Harmer CL 1996 Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 22:588–591.
  176. Fersht N, Vini L, A’Hern R, Harmer C 2001 The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 11: 1161–1168.
  177. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T 1996 Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305–310.
  178. Nguyen TD, Chassard JL, Lagarde P, Cutuli B, Le Fur R, Reme-Saumon M, Prevost B, Panis X, Verrelle P, Chaplain G 1992 Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes–the Radiotherapy Cooperative Group. Radiother Oncol 23:1–5.
  179. Schlumberger M, Gardet P, de Vathaire F, Sarrazin D, Travagli JP, Parmentier C 1991 External radiotherapy and chemotherapy in MTC patients. In: Calmette C (ed) Medullary Thyroid Carcinoma. Vol 211. INSERM/John Libbey Eurotext Ltd., Paris, pp 213–220.
  180. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC 2003 Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 98:356–362.
  181. Chiu AC, Delpassand ES, Sherman SI 1997 Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82:3637–3642.
  182. Kim IY, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD 2009 Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol [Epub ahead of print].
  183. Mont’Alverne F, Vallee JN, Cormier E, Guillevin R, Barragan H, Jean B, Rose M, Chiras J 2005 Percutaneous vertebroplasty for metastatic involvement of the axis. AJNR Am J Neuroradiol 26:1641–1645.
  184. Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Gronemeyer DH, Gevargez A, Ahrar K, Choti MA, de Baere TJ, Rubin J 2004 Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22:300–306.
  185. Callstrom MR, Charboneau JW 2007 Image-guided palliation of painful metastases using percutaneous ablation. Tech Vasc Interv Radiol 10:120–131.
  186. Thanos L, Mylona S, Galani P, Tzavoulis D, Kalioras V, Tanteles S, Pomoni M 2008 Radiofrequency ablation of osseous metastases for the palliation of pain. Skeletal Radiol 37:189–194.
  187. Simon CJ, Dupuy DE 2006 Percutaneous minimally invasive therapies in the treatment of bone tumors: thermal ablation. Semin Musculoskelet Radiol 10:137–144.
  188. Masala S, Manenti G, Roselli M, Mammucari M, Bartolucci DA, Formica V, Massari F, Simonetti G 2007 Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol. Anticancer Res 27:4259–4262.
  189. Kastler B, Jacamon M, Aubry S, Barral FG, Hadjidekov G, Sarlie`ve P, Saguet O, Lerais JM, Cadel G, Kovacs R, Boulahdour H, Pereira P 2007 [Combined bipolar radiofrequency and cementoplasty of bone metastases]. J Radiol 88:1242–1247. (In French.)
  190. Toyota N, Naito A, Kakizawa H, Hieda M, Hirai N, Tachikake T, Kimura T, Fukuda H, Ito K 2005 Radiofrequency ablation therapy combined with cementoplasty for painful bone metastases: initial experience. Cardiovasc Intervent Radiol 28:578–583.
  191. Papagelopoulos PJ, Mavrogenis AF, Soucacos PN 2007 Evaluation and treatment of pelvic metastases. Injury 38:509–520.
  192. Chiras J,AdemC, Vallee JN, Spelle L, Cormier E, RoseM2004 Selective intra-arterial chemoembolization of pelvic and spine bone metastases. Eur Radiol 14:1774–1780.
  193. Nagata Y, Mitsumori M, Okajima K, Mizowaki T, Fujiwara K, Sasai K, Nishimura Y, Hiraoka M, Abe M, Shimizu K, Kotoura Y 1998 Transcatheter arterial embolization for malignant osseous and soft tissue sarcomas. II. Clinical results. Cardiovasc Intervent Radiol 21:208–213.
  194. Layalle I, Flandroy P, Trotteur G, Dondelinger RF 1998 Arterial embolization of bone metastases: is it worthwhile? J Belge Radiol 81:223–225. 608
  195. Guzman R, Dubach-Schwizer S, Heini P, Lovblad KO, Kalbermatten D, Schroth G, Remonda L 2005 Preoperative transarterial embolization of vertebral metastases. Eur Spine J 14:263–268.
  196. Baba Y, Hayashi S, Ueno K, Nakajo M 2007 Bone cement used as an embolic agent for active bleeding in vertebroplasty of metastatic lesions. Acta Radiol 48:1024–1027.
  197. Boruban S, Sancak T, Yildiz Y, Sag˘ lik Y 2007 Embolization of benign and malignant bone and soft tissue tumors of the extremities. Diagn Interv Radiol 13:164–171.
  198. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G 2001 Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84:1586–1590.
  199. Mazzaglia PJ, Berber E, Milas M, Siperstein AE 2007 Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:10–19.
  200. Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP 2008 Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid 18:1105–1110.
  201. Lorenz K, Brauckhoff M, Behrmann C, Sekulla C, Ukkat J, Brauckhoff K, Gimm O, Dralle H 2005 Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138:986–993; discussion 993.
  202. Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M 2006 Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 91:2496–2499.
  203. Jensen RT 1999 Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin Gastrointest Dis 10:156–172.
  204. Alam MJ 1994 Chronic refractory diarrhoea: a manifestation of endocrine disorders. Dig Dis 12:46–61.
  205. Scherubl H, Raue F, Ziegler R 1990 Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116: 21–23.
  206. Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, Angeli A 1994 Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5:763–765.
  207. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB,McGuireWP, 3rd 1994 Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432–436.
  208. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE 1995 Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71:363–365.
  209. Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P 1995 A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol 6:77–79.
  210. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L 1998 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83:372–378.
  211. Petursson SR 1988 Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62:1899–1903.
  212. American Cancer Society 2009 Complementary and Alternative Therapies. Available at http://www.cancer.org/ docroot/ETO=ETO_5.asp?sitearea=ETO. Accessed February 21, 2009.
  213. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J 2006 Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705– 1711.
  214. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J 2006 Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 47:247–255.
  215. Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ 2005 Longterm efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 26:969–976.
  216. Pasieka JL, McEwan AJ, Rorstad O 2004 The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136:1218–1226.
  217. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB 2004 Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 151:15–27.
  218. Boughton D, Rosen L, Van Vugt A, Kurzrock R, Eschenberg M, Wiezorek J, Ingram M, Wang D, Stepan D, Herbst RS 2006 Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study. ASCO Annual Meeting Proceedings Part I 24:3030.
  219. Wells SA, Gosnell JE, Gagel RF, Moley JF, Pfister DG, Sosa JA, Skinner M, Krebs A, Hou J, Schlumberger M 2007 Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. ASCO Annual Meeting Proceedings Part I 25:6016.
  220. Kober F, Hermann M, Handler A, Krotia G 2007 Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. ASCO Annual Meeting Proceedings Part I 25: 14065.
  221. Lam ET, Ringel MD, Kloos RT, Collamore M, Arbogast D, Liang J, Hall N, Knopp MV, Wright J, Shah MH 2009 Anti-tumor activity of Sorafenib in patients with Metastatic Medullary Thyroid Carcinoma. Proceedings of the American Association for Cancer Research. Abstract 4513.
  222. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R 2008 A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 26:abstract 3522.
  223. Cox TM, Fagan EA, Hillyard CJ, Allison DJ, Chadwick VS 1979 Role of calcitonin in diarrhoea associated with medullary carcinoma of the thyroid. Gut 20:629–633.
  224. Rambaud JC, Jian R, Flourie B, Hautefeuille M, Salmeron M, Thuillier F, Ruskone A, Florent C, Chaoui F, Bernier JJ 1988 Pathophysiological study of diarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time. Gut 29:537–543.
  225. Vainas I, Koussis C, Pazaitou-Panayiotou K, Drimonitis A, Chrisoulidou A, Iakovou I, Boudina M, Kaprara A, Maladaki A 2004 Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res 23:549–559.
  226. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR, Culler MD, Degli Uberti EC 2006 Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab 91:2218–2224.
  227. Mahler C, Verhelst J, de Longueville M, Harris A 1990 Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33:261–269.
  228. Barbosa SL, Rodien P, Leboulleux S, Niccoli-Sire P, Kraimps JL, Caron P, Archambeaud-Mouveroux F, Conte-Devolx B, Rohmer V 2005 Ectopic adrenocorticotropic hormonesyndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid 15:618–623.
  229.  Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G 1996 Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 78:1114–1118.
  230. Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, Abbruzzese A, Lupoli G 2000 Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85:983–988.
  231. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK 2005 Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 90: 4955–4962.
  232. Smallridge RC, Bourne K, Pearson BW, Van Heerden JA, Carpenter PC, Young WF 2003 Cushing’s syndrome due to medullary thyroid carcinoma: diagnosis by proopiomelanocortin messenger ribonucleic acid in situ hybridization. J Clin Endocrinol Metab 88:4565–4568.
  233. McElduff A, Clifton-Bligh P, Posen S 1979 Metastatic medullary carcinoma of the thyroid complicated by Cushing’s syndrome. Med J Austr 1:186–188.
  234. Bourlet P, Dumousset E, Nasser S, Chabrot P, Pezet D, Thieblot P, Garcier JM, Boyer L 2007 Embolization of hepatic and adrenal metastasis to treat Cushing’s syndrome associated with medullary thyroid carcinoma: a case report. Cardiovasc Intervent Radiol 30:1052–1055.
  235. von Mach MA, Kann P, Piepkorn B, Bruder S, Beyer J 2002 [Cushing’s syndrome caused by paraneoplastic ACTH secretion 11 years after occurence of a medullary thyroid carcinoma]. Dtsch Med Wochenschr 127:850–852. (In German.)
  236. Winquist EW, Laskey J, Crump M, Khamsi F, Shepherd FA 1995 Ketoconazole in the management of paraneoplastic Cushing’s syndrome secondary to ectopic adrenocorticotropin production. J Clin Oncol 13:157–164.
  237. Mure A, Gicquel C, Abdelmoumene N, Tenenbaum F, Francese C, Travagli JP, Gardet P, Schlumberger M 1995 Cushing’s syndrome in medullary thyroid carcinoma. J Endocrinol Invest 18:180–185.
  238. Bjerner J, Nustad K, Norum LF, Olsen KH, Bormer OP 2002 Immunometric assay interference: incidence and prevention. Clin Chem 48:613–621.
  239. Wang TS, Ocal IT, Sosa JA, Cox H, Roman S 2008 Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid 18:889–894.
  240. Dora JM, da Silva Canalli MH, Capp C, Punales MK, Vieira JG, Maia AL 2008 Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 18:895–899.
  241. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E 1984 Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278–285.
  242. Mendelsohn G, Wells SA Jr, Baylin SB 1984 Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer 54:657–662.
  243. Seri M, Celli I, Betsos N, Claudiani F, Camera G, Romeo G 1997 A Cys634Gly substitution of the RET proto-oncogene in a familywith recurrence ofmultiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Clin Genet 51:86–90.
  244. Nunziata V, di Giovanni G, Lettera AM, D’Armiento M, Mancini M 1989 Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A. Henry Ford Hosp Med J 37:144–146.
  245.  Donovan DT, Levy ML, Furst EJ, Alford BR, Wheeler T, Tschen JA, Gagel RF 1989 Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant. Henry Ford Hosp Med J 37: 147–150.
  246. Khurana R, Agarwal A, Bajpai VK, Verma N, Sharma AK, Gupta RP, Madhusudan KP 2004 Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology 145:5465–5470.
  247. Nunziata V, Giannattasio R, Di Giovanni G, D’ArmientoMR, Mancini M 1989 Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple’s syndrome). Clin Endocrinol 30:57–63.
  248. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C 1999 Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 18:1369–1373.
  249. Borrego S, Wright FA, Fernandez RM, Williams N, Lopez- Alonso M, Davuluri R, Antinolo G, Eng C 2003 A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet 72:88–100.
  250. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD, Dunning AM, Ponder BA 2005 Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6268–6274.
  251. Costa P, Domingues R, Sobrinho LG, Bugalho MJ 2005 RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population. Endocrine 27:239–243.
  252. Cardot-Bauters C, Leteurtre E, Leclerc L, Vantyghem MC, Do Cao C, Wemeau JL, d’Herbomez M, Carnaille B, Barbu V, Pinson S, Pigny P 2008 Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma? Clin Endocrinol 69:506–510.
  253. Fugazzola L, Muzza M, Mian C, Cordella D, Barollo S, Alberti L, Cirello V, Dazzi D, Girelli ME, Opocher G, Beck- Peccoz P, Persani L 2008 RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. Clin Endocrinol 69:418–425.
  254. Weinhaeusel A, Scheuba C, Lauss M, Kriegner A, Kaserer K, Vierlinger K, Haas OA, Niederle B 2008 The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma. Thyroid 18:1269–1276.
  255. Ruiz-Llorente S, Montero-Conde C, Milne RL, Moya CM, Cebrian A, Leton R, Cascon A, Mercadillo F, Landa I, Borrego S, de Nanclares GP, Alvarez-Escola C, Diaz-Perez JA, Carracedo A, Urioste M, Gonzalez-Neira A, Benitez J, Santisteban P, Dopazo J, Ponder BA, Robledo M 2007 Association study of 69 genes in the Ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Res 67:9561–9567.
  256. Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Veelen W, Hoppener JW, Franklin DS 2007 Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis. Oncogene 26:554–570.
  257. Gujral TS, Singh VK, Jia Z, Mulligan LM 2006 Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res 66:10741– 10749.
  258. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, SantoroM, Stephan C, Grosios K,WartmannM, Cozens R, CaravattiG, FabbroD, LaneHA, Fagin JA2007 The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67:6956–6964.
  259. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M 2006 BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326–334.
  260. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibanez CF, McDonald NQ 2006 Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577–33587.
  261. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708–4713.
  262. Pigny P, Bauters C, Wemeau JL, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine MP, Kerckaert JP, Porchet N 1999 A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84:1700–1704.
  263. Fazioli F, Piccinini G, Appolloni G, Bacchiocchi R, Palmonella G, Recchioni R, Pierpaoli E, Silvetti F, Scarpelli M, Bruglia M, Melillo RM, Santoro M, Boscaro M, Taccaliti A 2008 A new germline point mutation in ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. Thyroid 18:775–782.
  264. Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM 2003 A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88:5438–5443.
  265. Bethanis S, Koutsodontis G, Palouka T, Avgoustis C, Yannoukakos D, Bei T, Papadopoulos S, Linos D, Tsagarakis S 2007 A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones (Athens) 6:152–156.
  266. Peppa M, Boutati E, Kamakari S, Pikounis V, Peros G, Panayiotides IG, Economopoulos T, Raptis SA, Hadjidakis D 2008 Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. Eur J Endocrinol 159:767–771.
  267. Sa´ez ME, Ruiz A, Cebria´n A, Morales F, Robledo M, Antin ˜ olo G, Borrego S 2000 A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation? Hum Mutat 15:122.
  268. Rey JM, Brouillet JP, Fonteneau-Allaire J, Boneu A, Bastie D, Maudelonde T, Pujol P 2001 Novel germline RET mutation segregating with papillary thyroid carcinomas. Genes Chromosomes Cancer 32:390–391.
  269. Ahmed SA, Snow-Bailey K, Highsmith WE, Sun W, Fenwick RG, Mao R 2005 Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn 7:283–288.
  270. Ercolino T, Lombardi A, Becherini L, Piscitelli E, Cantini G, Gagliano MS, Serio M, Luconi M, Mannelli M 2008 The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol 69:253–258.
  271. Igaz P, Patocs A, Racz K, Klein I, Varadi A, Esik O 2002 Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene. J Clin Endocrinol Metab 87:2994.
  272. Fialkowski EA, DeBenedetti MK, Moley JF, Bachrach B 2008 RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg 43:188–190.
  273. Kinlaw WB, Scott SM, Maue RA, Memoli VA, Harris RD, Daniels GH, Porter DM, Belloni DR, Spooner ET, Ernesti MM, Noll WW 2005 Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol 63:676–682.
  274. Yonekawa H, Sugitani I, Fujimoto Y, Arai M, Yamamoto N 2007 A family of multiple endocrine neoplasia type 2A (MEN 2A) with Cys630Tyr RET germline mutation: report of a case. Endocr J 54:531–535.
  275. Frank-Raue K 2008 Clinical update: genotype-phenotype correlation of RET mutations. Hot Thyroidology 2008; November:HT03=08. Available at http:==www .hotthyroidology.com=index.php. Accessed November 30, 2008.
  276. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Hoppner W 1998 A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770–774.
  277. Hoppner W, Dralle H, Brabant G 1998 Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. Hum Mutat Suppl 1:S128–130.
  278. Punales MK, Graf H, Gross JL, Maia AL 2003 RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab 88:2644–2649.
  279. Zhou YL, Zhu SX, Li JJ, Liu JB, Yin M, Xiao BY, Yu CL, Wang LM, Gu LQ, Cui B, Ning G, Li XY, Zhao YJ 2007 [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees]. Zhonghua Nei Ke Za Zhi [Chinese journal of internal medicine] 46:466– 470. (In Chinese.)
  280. Lemos MC, Carrilho F, Rodrigues FJ, Santos P, Carvalheiro M, Ruas MA, Regateiro FJ 2002 Early onset of medullary thyroid carcinoma in a kindred with multiple endocrine neoplasia type iia associated with cutaneous lichen amyloidosis. Endocr Pract 8:19–22.
  281. Hoppner W, Ritter MM 1997 A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 6:587–590.
  282. Vierhapper H, Bieglmayer C, Heinze G, Baumgartner- Parzer S 2004 Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. Thyroid 14:580–583.
  283. Colombo-Benkmann M, Li Z, Riemann B, Hengst K, Herbst H, Keuser R, Gross U, Rondot S, Raue F, Senninger N, Putzer BM, Frank-Raue K 2008 Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur J Endocrinol 158:811–816.
  284. D’Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, Filetti S 2006 Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. J Clin Endocrinol Metab 91:754–759.
  285. Vestergaard P, Vestergaard EM, Brockstedt H, Christiansen P 2007 Codon Y791F mutations in a large kindred: is prophylactic thyroidectomy always indicated? World J Surg 31:996–1001; discussion 1002–1004.
  286. Learoyd DL, Gosnell J, Elston MS, Saurine TJ, Richardson AL, Delbridge LW, Aglen JV, Robinson BG 2005 Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol 63:636–641.
  287. Recasens M, Oriola J, Fernandez-Real JM, Roig J, Rodriguez-Hermosa JI, Font JA, Galofre P, Lopez-Bermejo A, Ricart W 2007 Asymptomatic bilateral adrenal pheochromocytoma in a patient with a germline V804M mutation in the RET proto-oncogene. Clin Endocrinol 67: 29–33.
  288. Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD 2001 Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 38:784–787.
  289. Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, Hodgson S, Clarke S, Pierotti M, Ponder BA, Bongarzone I 2006 A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Mol Endocrinol 20:1633–1643.
  290. Prazeres HJ, Rodrigues F, Figueiredo P, Naidenov P, Soares P, Bugalho MJ, Lacerda M, Campos B, Martins TC 2006 Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clin Endocrinol 64:659–666.
  291. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C 1997 Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902–3904.
  292. Smith DP, Houghton C, Ponder BA 1997 Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213–1217.
  293. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH 1997 A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176–4178.
  294. Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF 1999 A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes 13:77–79.
  295. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF 2004 Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 89:4142–4145.
  296. Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO 2004 A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89:3521–3526.

Address reprint requests to:
Richard T. Kloos, M.D.
The Ohio State University
446 McCampbell Hall
1581 Dodd Drive
Columbus, OH 43210

E-mail: richard.kloos@osumc.edu